Literature DB >> 19625706

Nicked {beta}2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property.

Hisako Nakagawa1, Shinsuke Yasuda, Eiji Matsuura, Kazuko Kobayashi, Masahiro Ieko, Hiroshi Kataoka, Tetsuya Horita, Tatsuya Atsumi, Takao Koike.   

Abstract

Angiostatin was first discovered as a plasminogen fragment with antitumor/antiangiogenic property. One of the angiostatin isoforms, that is, angiostatin 4.5 (AS4.5), consisting of plasminogen kringle 1 to 4 and a most part of kringle 5, is produced by autoproteolysis and present in human plasma. beta2-glycoprotein I (beta2GPI) is proteolytically cleaved by plasmin in its domain V (nicked beta2GPI), resulting in binding to plasminogen. Antiangiogenic properties have been recently reported in nicked beta2GPI as well as in intact beta2GPI at higher concentrations. In the present study, we found significant binding of nicked beta2GPI to AS4.5 (K(D) = 3.27 x 10(6) M(-1)). Via this binding, nicked beta2GPI attenuates the antiangiogenic functions of AS4.5 in the proliferation of arterial/venous endothelial cells, in the extracellular matrix invasion and the tube formation of venous endothelial cells, and in vivo angiogenesis. In contrast, intact beta2GPI does not bind to AS4.5 or inhibit its antiangiogenic activity. Thus, nicked beta2GPI exerts dual effects on angiogenesis, that is, nicked beta2GPI promotes angiogenesis in the presence of AS4.5, whereas nicked beta2GPI inhibits angiogenesis at concentrations high enough to neutralize AS4.5. Our data suggest that plasmin-nicked beta2GPI promotes angiogenesis by interacting with plasmin-generated AS4.5 in sites of increased fibrinolysis such as thrombus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625706     DOI: 10.1182/blood-2008-12-190629

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Proteolytic processing of the extracellular scaffolding protein LEV-9 is required for clustering acetylcholine receptors.

Authors:  Luis Briseño-Roa; Jean-Louis Bessereau
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

2.  Structural and functional characterization of β2 -glycoprotein I domain 1 in anti-melanoma cell migration.

Authors:  Shr-Jeng Jim Leu; Tzong-Yi Lee; Shu-Wei Cheng; Meng-Ying Tsai; Yu-Shan Lin; Tzeon-Jye Chiou; Kai-Yao Huang; An-Na Chiang
Journal:  Cancer Sci       Date:  2019-05-15       Impact factor: 6.716

3.  In vivo evidence of angiogenesis inhibition by β2-glycoprotein I subfractions in the chorioallantoic membrane of chicken embryos.

Authors:  C M Baldavira; L F Gomes; L T De La Cruz; D A Maria; V L Capelozzi
Journal:  Braz J Med Biol Res       Date:  2021-01-15       Impact factor: 2.590

Review 4.  The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System.

Authors:  R Arreola-Diaz; A Majluf-Cruz; L E Sanchez-Torres; J Hernandez-Juarez
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

Review 5.  Primary antiphospholipid syndrome, Addison disease, and adrenal incidentaloma.

Authors:  Gabriela Medina; María Pilar Jiménez-Arellano; Andrés Muñoz-Solís; Erick Servín-Torres; Pablo Ramírez-Mendoza; Luis J Jara
Journal:  Clin Rheumatol       Date:  2020-03-07       Impact factor: 2.980

6.  Beta2 glycoprotein I-derived therapeutic peptides induce sFlt-1 secretion to reduce melanoma vascularity and growth.

Authors:  Haley Smalley; Jennifer M Rowe; Fernando Nieto; Jazmin Zeledon; Kellyn Pollard; John M Tomich; Sherry D Fleming
Journal:  Cancer Lett       Date:  2020-09-04       Impact factor: 8.679

7.  β2-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase.

Authors:  Wen-Chin Chiu; Tzeon-Jye Chiou; Meng-Ju Chung; An-Na Chiang
Journal:  PLoS One       Date:  2016-08-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.